| Company Name: |
BOC Sciences |
| Tel: |
1-631-485-4226; 16314854226 |
| Email: |
info@bocsci.com |
1H-Indole-4-carboxamide, 2-methyl-1-[5,6,7,8-tetrahydro-4-[(phenylmethyl)amino]pyrido[2,3-d]pyrimidin-2-yl]- manufacturers
- CB-5339
-
- $50.00
-
2026-07-14
- CAS:1863952-15-1
- Purity: 98.50%
- Supply Ability: 10g
|
| | 1H-Indole-4-carboxamide, 2-methyl-1-[5,6,7,8-tetrahydro-4-[(phenylmethyl)amino]pyrido[2,3-d]pyrimidin-2-yl]- Basic information |
| Product Name: | 1H-Indole-4-carboxamide, 2-methyl-1-[5,6,7,8-tetrahydro-4-[(phenylmethyl)amino]pyrido[2,3-d]pyrimidin-2-yl]- | | Synonyms: | 1H-Indole-4-carboxamide, 2-methyl-1-[5,6,7,8-tetrahydro-4-[(phenylmethyl)amino]pyrido[2,3-d]pyrimidin-2-yl]-;1-(4-(benzylamino)-5,6,7,8-tetrahydropyrido[2,3-d]pyrimidin-2-yl)-2-methyl-1H-indole-4-carboxamide;Dabigatran Impurity 127;p97-IN-1;H-Indole-4-carboxamide, 2-methyl-1-[5,6,7,8-tetrahydro-4-[(phenylmethyl)amino]pyrido[2,3-d]pyrimidin-2-yl]-;CB-5339 | | CAS: | 1863952-15-1 | | MF: | C24H24N6O | | MW: | 412.49 | | EINECS: | | | Product Categories: | | | Mol File: | 1863952-15-1.mol | ![1H-Indole-4-carboxamide, 2-methyl-1-[5,6,7,8-tetrahydro-4-[(phenylmethyl)amino]pyrido[2,3-d]pyrimidin-2-yl]- Structure](CAS/20210305/GIF/1863952-15-1.gif) |
| | 1H-Indole-4-carboxamide, 2-methyl-1-[5,6,7,8-tetrahydro-4-[(phenylmethyl)amino]pyrido[2,3-d]pyrimidin-2-yl]- Chemical Properties |
| Boiling point | 751.8±70.0 °C(Predicted) | | density | 1.38±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO : 41.67 mg/mL | | pka | 16.12±0.30(Predicted) | | form | Solid | | color | Off-white to yellow | | InChIKey | XDHFSLWWYBVSLN-UHFFFAOYSA-N | | SMILES | N1(C2=NC(NCC3=CC=CC=C3)=C3CCCNC3=N2)C2=C(C(C(N)=O)=CC=C2)C=C1C |
| | 1H-Indole-4-carboxamide, 2-methyl-1-[5,6,7,8-tetrahydro-4-[(phenylmethyl)amino]pyrido[2,3-d]pyrimidin-2-yl]- Usage And Synthesis |
| Uses | CB-5339 is an oral activity potent p97 inhibitor with an IC50 <30 nM. CB-5339 can be used for leukemia research[1]. CB-5339 extracted from WO2015109285A1 compound FF07. | | Biological Activity | CB-5339 is a second generation, potent and selective, orally bioavailable, ATP-competitive, small molecule inhibitor of valosin containing protein (VCP)/p97 [1,2]. CB-5339 is an ATP-competitive, small molecule inhibitor of p97 with IC50 of 53 nM [3].
CB-5339 effectively effect on a panel of 16 primary AML patient samples harboring diverse genetic backgrounds. The median IC50 value was 375 nM among these samples [1]. CB-5339 (200 to 1000 nM for 48 hours) induces in vitro loss of viability in AML cell lines (OCI-AML3, MOLM13, SET2 and HEL92.1.7 cells), as well as in fresh, patient-derived (PD) AML cells, including those with TP53 mutations and/or TP53 allelic loss, or with 3q26 (MECOM locus) lesions and EVI1 overexpression [2]. CB-5339 induced accumulation of polyubiquitylated proteins, retention of ERAD substrates, and lethal ER stress in cancer cells mediated by CHOP, DR5 and NOXA [2].
CB-5339 has higher bioavailability than CB-5083 [1]. Treatment with CB-5339 (90 mg/kg) reduced invasion of myeloid leukemia and prolonged survival in an MLL-AF9-driven PDX AML mouse model [1]. In a tail-vein infused, luciferase transduced, aggressive xenograft model of MOLM13 cells, after AML engraftment, co-treatment for 3 weeks with CB-5339 (50 mg/kg/day, PO) and either venetoclax (30 mg/kg/day, PO) or OTX015 (30 mg/kg/day, PO), as compared to treatment with vehicle or each drug alone, significantly reduced the AML burden and improved median and overall survival of the NSG mice, without inducing significant toxicity [2]. | | in vivo | CB-5339 (90 mg/kg for p.o.) decreases bone marrow leukemic infiltration and prolongs mice survival in MLL-AF9-driven patient-derived xenograft (PDX) AML mouse model[2].
| Animal Model: | MLL-AF9-driven patient-derived xenograft (PDX) AML model in C57BL/6 male mice[2] | | Dosage: | 90 mg/kg | | Administration: | oral gavage (p.o.) | | Result: | Decreased bone marrow leukemic infiltration and circulating leukemic cells.
Prolonged mice survival.
|
| | References | [1]. B Roux B, Vaganay C, Vargas J D, et al. Targeting acute myeloid leukemia dependency on VCP-mediated DNA repair through a selective second-generation small-molecule inhibitor[J]. Science translational medicine, 2021, 13(587): eabg1168.[2]. Fiskus W C, Das K, Mill C P, et al. Efficacy of Vcp/p97 Inhibitor, CB-5339, Alone and in Combinations Against High-Risk AML, Including Those with Genetic Lesion in TP53[J]. Blood, 2022, 140(Supplement 1): 8807-8808.[3]. Wang X, Wen T, Miao H, et al. Discovery of a new class of valosine containing protein (VCP/P97) inhibitors for the treatment of colorectal cancer[J]. Bioorganic & Medicinal Chemistry, 2022, 74: 117050. |
| | 1H-Indole-4-carboxamide, 2-methyl-1-[5,6,7,8-tetrahydro-4-[(phenylmethyl)amino]pyrido[2,3-d]pyrimidin-2-yl]- Preparation Products And Raw materials |
|